[Studies on formulation and bioavailability of benorilate tablets]

Area of Science:

• Pharmaceutical Sciences
• Pharmacokinetics
• Drug Delivery Systems

Context:

• Benorilate's bioavailability can be limited by its dissolution rate.
• Particle size reduction is a common strategy to enhance drug dissolution and absorption.
• Developing improved drug formulations is crucial for optimizing therapeutic outcomes.

Purpose:

• To develop a new tablet formulation (B) of benorilate with enhanced bioavailability.
• To compare the in vitro dissolution and in vivo pharmacokinetic profiles of tablet B against a reference formulation (tablet A).
• To investigate the effect of particle size reduction on benorilate's dissolution and bioavailability.

Summary:

• A new tablet formulation (B) was developed by reducing benorilate particle size, aiming to improve bioavailability.
• In vitro studies showed significantly higher dissolution rates and lower mean dissolution times for tablet B compared to tablet A.
• In vivo studies indicated no significant differences in key pharmacokinetic parameters (Cmax, Tp, AUC) for salicylic acid, but tablet B demonstrated a 125.59% relative bioavailability compared to tablet A.

Impact:

• The new formulation (B) offers a 25.59% increase in benorilate's relative bioavailability, suggesting improved drug delivery.
• This formulation advancement could lead to more effective therapeutic regimens for conditions treated with benorilate.
• The findings support particle size reduction as an effective strategy for enhancing the bioavailability of poorly soluble drugs.